NCT06111625 2023-11-01Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALLSichuan UniversityPhase 2 Recruiting20 enrolled
NCT06075212 2023-10-10Immune Reconstitution After Allo-HSCT and BlinatumomabSichuan UniversityUnknown20 enrolled
NCT06075238 2023-10-10Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCTSichuan UniversityPhase 2 Not yet recruiting68 enrolled